Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Whole-genome landscapes of major melanoma subtypes.

Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, Patch AM, Kakavand H, Alexandrov LB, Burke H, Jakrot V, Kazakoff S, Holmes O, Leonard C, Sabarinathan R, Mularoni L, Wood S, Xu Q, Waddell N, Tembe V, Pupo GM, De Paoli-Iseppi R, Vilain RE, Shang P, Lau LMS, Dagg RA, Schramm SJ, Pritchard A, Dutton-Regester K, Newell F, Fitzgerald A, Shang CA, Grimmond SM, Pickett HA, Yang JY, Stretch JR, Behren A, Kefford RF, Hersey P, Long GV, Cebon J, Shackleton M, Spillane AJ, Saw RPM, López-Bigas N, Pearson JV, Thompson JF, Scolyer RA, Mann GJ.

Nature. 2017 May 11;545(7653):175-180. doi: 10.1038/nature22071. Epub 2017 May 3.

PMID:
28467829
2.

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.

Lee JH, Long GV, Boyd S, Lo S, Menzies AM, Tembe V, Guminski A, Jakrot V, Scolyer RA, Mann GJ, Kefford RF, Carlino MS, Rizos H.

Ann Oncol. 2017 May 1;28(5):1130-1136. doi: 10.1093/annonc/mdx026.

PMID:
28327969
3.

Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma.

Jayawardana K, Schramm SJ, Tembe V, Mueller S, Thompson JF, Scolyer RA, Mann GJ, Yang J.

J Invest Dermatol. 2016 Jan;136(1):245-54. doi: 10.1038/JID.2015.355. Review.

4.

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.

Gray ES, Rizos H, Reid AL, Boyd SC, Pereira MR, Lo J, Tembe V, Freeman J, Lee JH, Scolyer RA, Siew K, Lomma C, Cooper A, Khattak MA, Meniawy TM, Long GV, Carlino MS, Millward M, Ziman M.

Oncotarget. 2015 Dec 8;6(39):42008-18. doi: 10.18632/oncotarget.5788.

5.

Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes.

Wilmott JS, Field MA, Johansson PA, Kakavand H, Shang P, De Paoli-Iseppi R, Vilain RE, Pupo GM, Tembe V, Jakrot V, Shang CA, Cebon J, Shackleton M, Fitzgerald A, Thompson JF, Hayward NK, Mann GJ, Scolyer RA.

Pathology. 2015 Dec;47(7):683-93. doi: 10.1097/PAT.0000000000000324. Erratum in: Pathology. 2016 Jan;48(1):104.

PMID:
26517638
6.

The BARD1 BRCT domain contributes to p53 binding, cytoplasmic and mitochondrial localization, and apoptotic function.

Tembe V, Martino-Echarri E, Marzec KA, Mok MT, Brodie KM, Mills K, Lei Y, DeFazio A, Rizos H, Kettle E, Boadle R, Henderson BR.

Cell Signal. 2015 Sep;27(9):1763-71. doi: 10.1016/j.cellsig.2015.05.011. Epub 2015 Jun 3.

PMID:
26022179
7.

MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis.

Tembe V, Schramm SJ, Stark MS, Patrick E, Jayaswal V, Tang YH, Barbour A, Hayward NK, Thompson JF, Scolyer RA, Yang YH, Mann GJ.

Pigment Cell Melanoma Res. 2015 May;28(3):254-66. doi: 10.1111/pcmr.12343. Epub 2015 Jan 5.

PMID:
25490969
8.

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.

Long GV, Fung C, Menzies AM, Pupo GM, Carlino MS, Hyman J, Shahheydari H, Tembe V, Thompson JF, Saw RP, Howle J, Hayward NK, Johansson P, Scolyer RA, Kefford RF, Rizos H.

Nat Commun. 2014 Dec 2;5:5694. doi: 10.1038/ncomms6694.

PMID:
25452114
9.

Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma.

Dutton-Regester K, Kakavand H, Aoude LG, Stark MS, Gartside MG, Johansson P, O'Connor L, Lanagan C, Tembe V, Pupo GM, Haydu LE, Schmidt CW, Mann GJ, Thompson JF, Scolyer RA, Hayward NK.

Pigment Cell Melanoma Res. 2013 Nov;26(6):852-60. doi: 10.1111/pcmr.12153. Epub 2013 Aug 23.

PMID:
23890154
10.

Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression.

Long GV, Wilmott JS, Haydu LE, Tembe V, Sharma R, Rizos H, Thompson JF, Howle J, Scolyer RA, Kefford RF.

Pigment Cell Melanoma Res. 2013 Jul;26(4):499-508. doi: 10.1111/pcmr.12098. Epub 2013 May 3.

PMID:
23557327
11.

Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine.

Wilmott JS, Tembe V, Howle JR, Sharma R, Thompson JF, Rizos H, Lo RS, Kefford RF, Scolyer RA, Long GV.

Mol Cancer Ther. 2012 Dec;11(12):2704-8. doi: 10.1158/1535-7163.MCT-12-0530. Epub 2012 Sep 7.

12.

Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors.

Anforth R, Tembe V, Blumetti T, Fernandez-Peñas P.

Pigment Cell Melanoma Res. 2012 Sep;25(5):569-72. doi: 10.1111/j.1755-148X.2012.01031.x. Epub 2012 Aug 6.

PMID:
22726224
13.

A high-throughput panel for identifying clinically relevant mutation profiles in melanoma.

Dutton-Regester K, Irwin D, Hunt P, Aoude LG, Tembe V, Pupo GM, Lanagan C, Carter CD, O'Connor L, O'Rourke M, Scolyer RA, Mann GJ, Schmidt CW, Herington A, Hayward NK.

Mol Cancer Ther. 2012 Apr;11(4):888-97. doi: 10.1158/1535-7163.MCT-11-0676. Epub 2012 Mar 1.

14.

Identification of TFG (TRK-fused gene) as a putative metastatic melanoma tumor suppressor gene.

Dutton-Regester K, Aoude LG, Nancarrow DJ, Stark MS, O'Connor L, Lanagan C, Pupo GM, Tembe V, Carter CD, O'Rourke M, Scolyer RA, Mann GJ, Schmidt CW, Herington A, Hayward NK.

Genes Chromosomes Cancer. 2012 May;51(5):452-61. doi: 10.1002/gcc.21932. Epub 2012 Jan 17.

PMID:
22250051
15.
16.

Protein trafficking in response to DNA damage.

Tembe V, Henderson BR.

Cell Signal. 2007 Jun;19(6):1113-20. Epub 2007 Mar 15. Review.

PMID:
17391916
17.

Nuclear targeting and cell cycle regulatory function of human BARD1.

Schüchner S, Tembe V, Rodriguez JA, Henderson BR.

J Biol Chem. 2005 Mar 11;280(10):8855-61. Epub 2005 Jan 4.

18.

Issues arising from the prenatal diagnosis of some rare trisomy mosaics--the importance of cryptic fetal mosaicism.

Daniel A, Wu Z, Darmanian A, Malafiej P, Tembe V, Peters G, Kennedy C, Adès L.

Prenat Diagn. 2004 Jul;24(7):524-36. Review.

PMID:
15300743
19.

The relationship between physicochemical properties, in vitro activity and pharmacokinetic profiles of analogues of diamine-containing efflux pump inhibitors.

Watkins WJ, Landaverry Y, Léger R, Litman R, Renau TE, Williams N, Yen R, Zhang JZ, Chamberland S, Madsen D, Griffith D, Tembe V, Huie K, Dudley MN.

Bioorg Med Chem Lett. 2003 Dec 1;13(23):4241-4.

PMID:
14623009
20.
21.

Insulin-like growth factor I increases renal 1,25(OH)2D3 biosynthesis during low-P diet in adult rats.

Wong MS, Sriussadaporn S, Tembe VA, Favus MJ.

Am J Physiol. 1997 Jun;272(6 Pt 2):F698-703.

PMID:
9227629
22.

Karyotype 69,XXX/47,XX,+15 in a 2 1/2 year old child.

Dean J, Cohen G, Kemp J, Robson L, Tembe V, Hasselaar J, Webster B, Lammi A, Smith A.

J Med Genet. 1997 Mar;34(3):246-9.

23.

Structure-function relationship of human parathyroid hormone in the regulation of vitamin D receptor expression in osteoblast-like cells (ROS 17/2.8).

Sriussadaporn S, Wong MS, Whitfield JF, Tembe V, Favus MJ.

Endocrinology. 1995 Sep;136(9):3735-42.

PMID:
7649079
24.

Loss of parathyroid hormone-stimulated 1,25-dihydroxyvitamin D3 production in aging does not involve protein kinase A or C pathways.

Friedlander J, Janulis M, Tembe V, Ro HK, Wong MS, Favus MJ.

J Bone Miner Res. 1994 Mar;9(3):339-45.

PMID:
8191927
25.

Increased intestinal vitamin D receptor in genetic hypercalciuric rats. A cause of intestinal calcium hyperabsorption.

Li XQ, Tembe V, Horwitz GM, Bushinsky DA, Favus MJ.

J Clin Invest. 1993 Feb;91(2):661-7.

26.

Response of genetic hypercalciuric rats to a low calcium diet.

Kim M, Sessler NE, Tembe V, Favus MJ, Bushinsky DA.

Kidney Int. 1993 Jan;43(1):189-96.

27.
28.
29.

The use of pharmacologic agents to study mechanisms of intestinal calcium transport.

Favus MJ, Tembe V.

J Nutr. 1992 Mar;122(3 Suppl):683-6. doi: 10.1093/jn/122.suppl_3.683. Review.

PMID:
1542031
30.

Acidosis inhibits 1,25-(OH)2D3 but not cAMP production in response to parathyroid hormone in the rat.

Ro HK, Tembe V, Krug T, Yang PY, Bushinsky DA, Favus MJ.

J Bone Miner Res. 1990 Mar;5(3):273-8.

PMID:
2159208
31.

Effects of quinacrine on calcium active transport by rat intestinal epithelium.

Favus MJ, Tembe V, Tanklefsky MD, Ambrosic KA, Nellans HN.

Am J Physiol. 1989 Nov;257(5 Pt 1):G818-22.

PMID:
2596612
32.

Effects of 1,25(OH)2D3 on enterocyte basolateral membrane Ca transport in rats.

Favus MJ, Tembe V, Ambrosic KA, Nellans HN.

Am J Physiol. 1989 Mar;256(3 Pt 1):G613-7.

PMID:
2923217
33.

Evidence for in vivo upregulation of the intestinal vitamin D receptor during dietary calcium restriction in the rat.

Favus MJ, Mangelsdorf DJ, Tembe V, Coe BJ, Haussler MR.

J Clin Invest. 1988 Jul;82(1):218-24.

34.

Uric acid saturation in calcium nephrolithiasis.

Coe FL, Strauss AL, Tembe V, Le Dun S.

Kidney Int. 1980 May;17(5):662-8.

35.

Urinary saturation measurements in calcium nephrolithiasis.

Weber DV, Coe FL, Parks JH, Dunn MS, Tembe V.

Ann Intern Med. 1979 Feb;90(2):180-4.

PMID:
443649
36.

Sodium urate accelerates precipitation of calcium oxalate in vitro.

Coe FL, Lawton RL, Goldstein RB, Tembe V.

Proc Soc Exp Biol Med. 1975 Sep;149(4):926-9.

PMID:
241080
37.

A clinico-pathologic study of snakebite cases.

Tembe VS, Sant SM, Purandare NM.

J Postgrad Med. 1975 Jan;21(1):36-47. No abstract available.

PMID:
1177165
38.

Lesions produced by Echis carinatus venom in experimental animals.

Sant SM, Tembe VS, Salgaonkar DS, Purandare NM.

J Postgrad Med. 1974 Apr;20(2):70-9. No abstract available.

PMID:
4212122
39.

Traumatic fat embolization (a study of 100 consecutive autopsies).

Kinare SG, Tembe VS, Kher YR.

J Postgrad Med. 1973 Oct;19(4):153-60. No abstract available.

PMID:
4793637

Supplemental Content

Support Center